Terms: = Leukemia AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
91 results:
1. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract] [Full Text] [Related]
2. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
[TBL] [Abstract] [Full Text] [Related]
3.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract] [Full Text] [Related]
4. Epigenetic vulnerabilities of leukemia harboring inactivating ezh2 mutations.
Alqazzaz MA; Luciani GM; Vu V; Machado RAC; Szewczyk MM; Adamson EC; Cheon S; Li F; Arrowsmith CH; Minden MD; Barsyte-Lovejoy D
Exp Hematol; 2024 Feb; 130():104135. PubMed ID: 38072134
[TBL] [Abstract] [Full Text] [Related]
5. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
Zhang L; Dong H
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
[TBL] [Abstract] [Full Text] [Related]
6. [Characteristics of genetic variants in 134 patients with Acute myeloid leukemia].
He M; Zhao X; Tian H; Zhang S; Zhao F; Zhang X; Wu T
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Oct; 40(10):1222-1227. PubMed ID: 37730221
[TBL] [Abstract] [Full Text] [Related]
7. Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.
Giudice V; Serio B; Errichiello S; Ferrara I; Galdiero A; Bertolini A; Visconti R; De Novellis D; Guariglia R; Luponio S; Morini D; Della Corte AM; Sessa AM; Verdesca F; Langella M; Izzo B; Selleri C
Eur J Haematol; 2023 Nov; 111(5):729-741. PubMed ID: 37501402
[TBL] [Abstract] [Full Text] [Related]
8. [Analysis of epigenetic modification gene mutations among patients with acute myeloid leukemia].
Wei J; Qiu H; Zhou H; Chen Z; Miao L; Wang Y; Zhao L; Cai Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Apr; 40(4):435-441. PubMed ID: 36972938
[TBL] [Abstract] [Full Text] [Related]
9. Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Kurahashi Y; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Yoshida-Sakai N; Fukuda-Kurahashi Y; Yamashita S; Hattori N; Nakamura H; Kawaguchi A; Ushijima T; Sueoka E; Kimura S
Blood Adv; 2023 Apr; 7(8):1545-1559. PubMed ID: 36516085
[TBL] [Abstract] [Full Text] [Related]
10. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract] [Full Text] [Related]
11. Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia.
Lackner D; Geissler K
Wien Med Wochenschr; 2023 Feb; 173(1-2):27-33. PubMed ID: 36414855
[TBL] [Abstract] [Full Text] [Related]
12. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
[TBL] [Abstract] [Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia.
Song GY; Kim T; Ahn SY; Jung SH; Kim M; Yang DH; Lee JJ; Choi SH; Kim MY; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Park SK; Kim SH; Zhang Z; Ahn JS; Kim HJ; Kim DDH
Bone Marrow Transplant; 2022 Dec; 57(12):1810-1819. PubMed ID: 36151367
[TBL] [Abstract] [Full Text] [Related]
14. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K; Makita S; Nosaka K; Yoshimitsu M; Utsunomiya A; Kusumoto S; Morishima S; Tsukasaki K; Kawamata T; Ono T; Rai S; Katsuya H; Ishikawa J; Yamada H; Kato K; Tachibana M; Kakurai Y; Adachi N; Tobinai K; Yonekura K; Ishitsuka K
Blood; 2023 Mar; 141(10):1159-1168. PubMed ID: 36150143
[TBL] [Abstract] [Full Text] [Related]
15. A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.
Wang X; Hong Y; Meng S; Gong W; Ren T; Zhang T; Liu X; Li L; Qiu L; Qian Z; Zhou S; Zhao M; Zhai Q; Meng B; Ren X; Zhang H; Wang X
Clin Immunol; 2022 Oct; 243():109105. PubMed ID: 36055572
[TBL] [Abstract] [Full Text] [Related]
16. Clinical Significance of ezh2 in Acute Myeloid leukemia.
Jiao W; Liu Y; Bao Y
Comput Intell Neurosci; 2022; 2022():8741989. PubMed ID: 36052036
[TBL] [Abstract] [Full Text] [Related]
17. CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia.
Maciel ALT; Wolch K; Emerenciano M; Mansur MB
Genes Chromosomes Cancer; 2022 Jul; 61(7):437-442. PubMed ID: 35253299
[TBL] [Abstract] [Full Text] [Related]
18. A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia.
Ren Z; Kim A; Huang YT; Pi WC; Gong W; Yu X; Qi J; Jin J; Cai L; Roeder RG; Chen WY; Wang GG
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217626
[TBL] [Abstract] [Full Text] [Related]
19. Lab tests for MPN.
Moncada A; Pancrazzi A
Int Rev Cell Mol Biol; 2022; 366():187-220. PubMed ID: 35153004
[TBL] [Abstract] [Full Text] [Related]
20. Histone Modifications and Their Targeting in Lymphoid Malignancies.
Fernández-Serrano M; Winkler R; Santos JC; Le Pannérer MM; Buschbeck M; Roué G
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008680
[TBL] [Abstract] [Full Text] [Related]
[Next]
